Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids.
OBJECTIVE
To investigate the effects of raloxifene, on serum lipids and high-sensitivity C-reactive protein (hs-CRP) in healthy postmenopausal women.


METHODS
We studied the effect of raloxifene, on serum lipids and hs-CRP in 85 healthy postmenopausal women. Participants were randomly assigned to 60 mg daily raloxifene (43 subjects) for 6 months; the rest of the subjects were in the control group. Serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglyceride and hs-CRP levels were measured at baseline and at the sixth month in both groups.


RESULTS
Raloxifene treatment resulted in a 26% reduction in serum hs-CRP concentrations at the sixth month, compared with the baseline levels (P < 0.05). At the sixth month, TC and LDL-C levels were significantly reduced by 60 mg daily raloxifene (6.8 and 5.6%, respectively) when compared with both the baseline levels and the control group.


CONCLUSIONS
The results of our study showed that raloxifene at a dose of 60 mg daily reduces serum TC, LDL-C and hs-CRP levels significantly in healthy postmenopausal women. According to the results of the current study, we suggest that raloxifene may have a favorable effect on the prevention of cardiovascular disease in healthy postmenopausal women.
Oztas
Efser
E
Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Ankara, Turkey. erkinous@yahoo.com
Kurtay
Gulay
G
D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D017698:Postmenopause / Q000097:blood*; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage* / Q000009:adverse effects; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage* / Q000009:adverse effects
D008055:Lipids; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D002097:C-Reactive Protein; D002784:Cholesterol